PGR and neoplasm: By contrast, PR-low/TP53m tumours rarely demonstrate such mutations; however, around one third (31.6%, 6 of 19) display mutation of BRCA1/2, suggesting exploration of poly-(ADP-ribose) polymerase (PARP) inhibitor efficacy in this population is warranted.